- $593.15m
- $541.47m
- $43.47m
- 38
- 13
- 96
- 47
Annual balance sheet for CorMedix, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 46.3 | 65.5 | 58.8 | 76 | 51.7 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.003 | 0.045 | 0 | — | 51.7 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 48.2 | 66.5 | 59.6 | 79.5 | 115 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.13 | 2.37 | 2.38 | 2.51 | 2.32 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 49.3 | 68.9 | 62 | 82.1 | 119 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4.16 | 5.35 | 6.31 | 11.4 | 33.8 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 5.09 | 6.15 | 6.98 | 11.9 | 34.2 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 44.2 | 62.8 | 55.1 | 70.1 | 84.7 |
Total Liabilities & Shareholders' Equity | 49.3 | 68.9 | 62 | 82.1 | 119 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |